Patents by Inventor Rob Oberlender
Rob Oberlender has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7662787Abstract: The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Type: GrantFiled: May 7, 2007Date of Patent: February 16, 2010Assignee: Shire LLCInventors: Travis Mickle, Suma Krishnan, Barney Bishop, Christopher Lauderback, James Scott Moncrief, Rob Oberlender, Thomas Piccariello, Bernhard J. Paul, Christopher A. Verbicky
-
Patent number: 7223735Abstract: The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Type: GrantFiled: June 1, 2004Date of Patent: May 29, 2007Assignee: New River Pharmaceuticals Inc.Inventors: Travis Mickle, Suma Krishnan, James Scott Moncrief, Christopher Lauderback, Barney Bishop, Rob Oberlender, Thomas Piccariello
-
Publication number: 20070042955Abstract: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Type: ApplicationFiled: April 10, 2006Publication date: February 22, 2007Applicant: New River Pharmaceuticals Inc.Inventors: Travis Mickle, Suma Krishnan, Barney Bishop, Christopher Lauderback, James Moncrief, Rob Oberlender, Thomas Piccariello
-
Patent number: 7105486Abstract: The invention describes compounds, compositions and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Type: GrantFiled: June 1, 2004Date of Patent: September 12, 2006Assignee: New River Pharmaceuticals Inc.Inventors: Travis Mickle, Suma Krishnan, Barney Bishop, Christopher Lauderback, James Scott Moncrief, Rob Oberlender, Thomas Piccariello
-
Publication number: 20050054561Abstract: The invention describes compounds, compositions and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Type: ApplicationFiled: June 1, 2004Publication date: March 10, 2005Inventors: Travis Mickle, Suma Krishnan, Barney Bishop, Christopher Lauderback, James Moncrief, Rob Oberlender, Thomas Piccariello
-
Publication number: 20050038121Abstract: The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Type: ApplicationFiled: June 1, 2004Publication date: February 17, 2005Applicant: New River Pharmaceuticals Inc.Inventors: Travis Mickle, Suma Krishnan, Barney Bishop, Christopher Lauderback, James Moncrief, Rob Oberlender, Thomas Piccariello